FIELD: pharmacology.
SUBSTANCE: invention relates to a compound of the general formula
having an imidazo[1,2-b]pyridazine structure, or a pharmacologically acceptable salt thereof and a pharmaceutical composition comprising such a compound. In the formula R1, G, T, Y1, Y2, Y3 and Y4 have values indicated in the claims.
EFFECT: compounds of the formula are useful for treatment of a tumour through an inhibitory effect on the enzymatic activity of its ROS1 kinase and the inhibitory effect on the enzyme kinase NTRK.
48 cl, 25 tbl, 150 ex
Title | Year | Author | Number |
---|---|---|---|
USING EP4 RECEPTOR LIGANDS IN TREATMENT OF IL-6-MEDIATED DISEASES | 2003 |
|
RU2285527C2 |
CYNNAMIDE COMPOUND | 2005 |
|
RU2361872C2 |
CYCLOALKANE-1,3-DIAMINE DERIVATIVE | 2019 |
|
RU2793247C2 |
NEW PYRIDINE DERIVATIVE AND PYRIMIDINE DERIVATIVE (1) | 2005 |
|
RU2330021C2 |
DERIVATIVES OF DIAMINES | 2002 |
|
RU2319699C2 |
DISPIROPYRROLIDINE DERIVATIVES | 2012 |
|
RU2612534C2 |
ARYL-SUBSTITUTED CARBOXAMIDE DERIVATIVES AS CALCIUM OR SODIUM CHANNEL BLOCKERS | 2010 |
|
RU2575168C2 |
CYCLOPROPANE COMPOUNDS | 2011 |
|
RU2571414C2 |
DIAMINE DERIVATIVES | 2002 |
|
RU2314303C2 |
DERIVATIVES OF CARBAPENEM, THEIR USING FOR PREPARING PHARMACEUTICAL COMPOSITION, PHARMACEUTICAL COMPOSITION BASED ON THEREOF AND METHOD FOR TREATMENT AND/OR PROPHYLAXIS OF INFECTIOUS DISEASES | 2001 |
|
RU2276154C2 |
Authors
Dates
2017-11-17—Published
2013-06-03—Filed